What is RNAC's P/E ratio?

CARTESIAN THERAPEUTICS INC. (RNAC) currently trades at a P/E ratio of 14.30.

CARTESIAN THERAPEUTICS INC. reports a Return on Equity (ROE) of 102.47%.

What is RNAC's dividend yield?

CARTESIAN THERAPEUTICS INC. offers a dividend yield of 0.00%.

What is RNAC's Quality Score?

Our AI rates RNAC's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy RNAC?

Our AI Timing Score for RNAC is 55 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does RNAC belong to?

CARTESIAN THERAPEUTICS INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

RNAC (NASDAQ) Stock Analysis | CARTESIAN THERAPEUTICS INC.

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

RNAC AI Analysis Summary

Our AI summary for RNAC: CARTESIAN THERAPEUTICS INC. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 14.30, ROE of 102.47%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 55/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

RNAC

CARTESIAN THERAPEUTICS INC.

US:NASDAQ STOCK Healthcare >> Biotechnology News 98

USD 7.80

0.07 (0.91%) Day Change

Watchlist Portfolio Compare Chart

14.30

P/E

-0.03

D/E

102.5%

ROE

-52.6%

ROA

0.00%

Div Yield

-0.07

PEG

CARTESIAN THERAPEUTICS INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 7.80 Price 0.07 (0.91%) Day Change	NEWS SCORE: 98

RNAC, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROA is relatively low.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	98
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	7.80
PBV / Sector	-1.53 / 5.20
Earning Per Share	-5.21

PE / Sector	14.30 / 19.97
PEG or PE/Growth / Sector	-0.07 / 1.22
Average 1M Daily Value	1.17 M GREAT
Average 1W Daily Value	0.90 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-8,550.65 / 98.71
NPM Average (%) / Sector	-2,844.24 / -1,721.76
NPM Change Average (%) / Sector	-124.26 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-52.63 / 27.02
ROA Average (%) / Sector	-33.02 / -368.17
ROA Change Average (%) / Sector	-86.57 / 5,404.12
ROE (%) / Sector	102.47 / 3.47 GREAT
ROE Average (%) / Sector	286.31 / 6.51 GREAT
ROE Change Average (%) / Sector	530.30 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:25
Symbol	RNAC
Name	CARTESIAN THERAPEUTICS INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	29.38 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	227.12 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 7495 New Horizon Way, Frederick, MD, United States, 21703

Phone: 301 348 8698

Website: https://www.cartesiantherapeutics.com

Employees: 75

Sector: Healthcare >> Biotechnology

Description: Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.